How Generalizable Are Cardiovascular Outcome Trials of Sodium-Glucose Co-Transporter-2 Inhibitors? A National Database Study: Study Protocol

INTRODUCTION: Sodium-glucose co-transporter-2 (SGLT2) inhibitors are oral antihyperglycemic agents for the treatment of people with type 2 diabetes (T2DM). Two recent cardiovascular outcome trials (CVOTs), the EMPA-REG OUTCOME trial and CANVAS Program, have demonstrated that SGLT2 inhibitors have ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Hinton, William, Feher, Michael D., Munro, Neil, de Lusignan, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531500/
https://www.ncbi.nlm.nih.gov/pubmed/31041781
http://dx.doi.org/10.1007/s13300-019-0620-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531500/
https://www.ncbi.nlm.nih.gov/pubmed/31041781
http://dx.doi.org/10.1007/s13300-019-0620-8

Ejemplares similares